Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 1 2Phase NA 1Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 3Esophageal Squamous Cell Carcinoma 3Adenocarcinoma Of Esophagus 3Esophageal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Skin Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Esophageal Diseases 1Carcinoma, Squamous Cell 1Carcinoma, Basal Cell 1Barrett Esophagus 1Adenocarcinoma 1

Interventions

Oxaliplatin 67Capecitabine 60Fluorouracil 58Bevacizumab 54Gemcitabine 51Paclitaxel 50Leucovorin 50Irinotecan 40Docetaxel 39Carboplatin 39Cisplatin 38pembrolizumab 37Nivolumab 37Cetuximab 35Sunitinib 25Trastuzumab 24Radiosurgery 24Radiotherapy 21Doxorubicin 21Cyclophosphamide 21Panitumumab 20Drug Therapy 19Pemetrexed 18Everolimus 18Sorafenib 17Interleukin-2 16Fulvestrant 16Albumin-Bound Paclitaxel 16atezolizumab 15Erlotinib Hydrochloride 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Neoplasm Metastasis × Itraconazole × Clear all
NCT01450683 2017-04-11

Study of Itraconazole in Castrate-resistant Prostate Cancer (CRPC) Post-chemotherapy

Stanford University

Phase 2 Terminated
4 enrolled 4 charts
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡